Dapagliflozin: a sodium –glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

Cardiac remodeling is one of the major risk factors for heart failure. In patients with type 2 diabetes, sodium –glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of the first hospitalization for heart...

Source: Cardiovascular Diabetology - June 11, 2021 Category: Cardiology Authors: Yuze Zhang, Xiaoyan Lin, Yong Chu, Xiaoming Chen, Heng Du, Hailin Zhang, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, Jinzhang Zeng, Ke Ma and Dajun Chai Tags: Original investigation Source Type: research